Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 05, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares, specifically regarding the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a specific employee retirement fund.
Material Changes
The primary material change reported is an increase in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan. As of March 31, 2005, the fund's holdings increased from 18,343,766 to 18,371,364 shares. This movement occurred at an average price of $45.86 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that two directors, Dr. J.P. Garnier and Dr. T. Yamada, are potentially interested in the shares held in the fund in the same capacity as other employees or former employees.
Key Facts for Investor Verification
- The increase in ADR holdings (27,598 shares) was driven by fund movements rather than direct director trading.
- The average transaction price for the fund movement was $45.86.
- Directors Dr. J.P. Garnier and Dr. T. Yamada have indirect interests in these shares through the discretionary employee fund.
- No financial performance data is included in this specific filing.